Good morning, everyone, and how are you today? We are doing just fine, thank you, despite a late-night trek to the STAT nerve center. Of course, this calls for a few cups of stimulation as we adjust and dig in for another busy day. And when are there not-busy days? No doubt, you can relate. So time to get cracking. Here are a few items of interest to help you on your own journey. Hope all goes well today and, of course, please do keep in touch.

Washington law firms are preparing for a boom in business from a projected Democratic takeover of the House in 2019, anticipating that drug makers will be among the companies needing help navigating a flurry of oversight investigations, Politico explains. Washington lawyers are crafting memos for clients describing the inquiries they could face next year and which lawmakers might lead the relevant House committees. Others are reaching out to corporations they believe will need new representation, explaining how they would keep them out of the crosshairs of Democratic-led probes.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy